Senderowicz AM, Headlee D, Stinson SF, et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin - dependent kinase inhibitor, in patients with refractory neoplasms.
Phase I Study of MK - 3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed / Refractory or Disseminated Malignant Neoplasm